Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis

References

• Herrmann J. Periprocedural myocardial injury: 2005 update. Eur Heart J. 2005;26:2493–519.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/ WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525–38.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406–11.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, . Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004;110:674–8.
   PubMed Web of Science ®Google Scholar
• Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, . Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25:1822–8.
   PubMed Web of Science ®Google Scholar
• Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, . Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272–8.
   PubMed Web of Science ®Google Scholar
• Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, . The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2008 Aug 13 (Epub ahead of print).
   Google Scholar
• Veselka J, Zemánek D, Hájek P, Malý M, Adlová R, Martinkovicová L, . Effect of two-day atorvastatin pre-treatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. Am J Cardiol. 2009;104:630–3.
   Google Scholar
• Briguori C. NAPLES (Novel Approaches for Preventing or Limiting Event Study) II Trial: Impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. Presented at 58th annual scientific session of American College of Cardiology 2009 in Orlando, USA on 30 March 2009. Available at: http://assets.cardiosource.com/NAPLESII_Briguori.ppt. accessed on April 30th 2009.
   Google Scholar
• Bozbas H, Yildirir A, Mermer S, Konas D, Atar I, Aydinalp A, . Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention? Adv Ther. 2007;24:493–504.
   Google Scholar
• Hara H, Nakamura M, Yokouchi I, Kimura K, Nemoto N, Ito S, . Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study. Ther Adv Cardiovasc Dis. 2009;3:357–65.
   Google Scholar
• Egger M, Ebrahim S, Smith GD. Where now for meta-analysis? Int J Epidemiol. 2002;31:1–5.
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, . Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331–7.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, . A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J. 1999; 20:58–69.
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
   PubMed Web of Science ®Google Scholar
• Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, . Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation. 2002;105:554–6.
   Google Scholar
• Mulukutla SR, Marroquin OC, Smith C, Varghese R, Anderson WD, Lee JS, . Effect of statin therapy prior to elective percutaneous coronary intervention of frequency of periprocedural myocardial injury. Am J Cardiol. 2004;94:1363–8.
   Google Scholar
• Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, . Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation. 2002;106:2180–3.
   PubMed Web of Science ®Google Scholar
• Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcomes. Catheter Cardiovasc Interv. 2004;62:193–7.
   Google Scholar
• Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, . Relation of inflammation and benefit of statins after percuatneous coronary inteventions. Circulation. 2003;107:1750–6.
   PubMed Web of Science ®Google Scholar
• Auguadro C, Manfredi M, Scalise F, Mortara A, Specchia G. Protective role of chronic statin therapy in reducing myocardial damage during percutaneous coronary intervention. J Cardiovasc Med (Hagerstown). 2006;7:416–21.
   Google Scholar
• Gurm HS, Breitbart Y, Vivekanathan D, Yen MH, Fathi R, Ziada KM, . Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy—a propensity-adjusted analysis. Am Heart J. 2006;151 suppl:e1031–6.
   Google Scholar
• Veselka J, Prochazkova S, Duchonova R, Homolova I, Tesar D, Bybee KA. Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Heart Vessels. 2006;21:146–51.
   Google Scholar
• Ebrahimi R, Saleh J, Toggart E, Shah AP, Azmoon S, Babaei H, . Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. J Invasive Cardiol. 2008;20:292–5.
   Google Scholar
• Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005;96:54F–60F.
   PubMed Web of Science ®Google Scholar
• Wassmann S, Faul A, Hennen B, Sheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res. 2003;93:e98–103.
   PubMed Web of Science ®Google Scholar
• Hinoi T, Matsuo S, Tadehara F, Tsujiyama S, Yamakido M. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol. 2005;96:89–91.
   PubMed Web of Science ®Google Scholar
• Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, . Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412–9.
   PubMed Web of Science ®Google Scholar
• Jones SP, Lefer DJ. Cardioprotective action of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand. 2001;173:139–43.
   Google Scholar
• Notarbartolo A, Davì G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, . Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hyper-cholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247–51.
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64–70.
   PubMed Web of Science ®Google Scholar
• Correia LC, Spósito AC, Lima JC, Magalhães LP, Passos LC, Rocha MS, . Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol. 2003;92:298–301.
   Google Scholar
• Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, . Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J. 2005;149:451–7.
   PubMed Web of Science ®Google Scholar
• Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, . High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560–6.
   PubMed Web of Science ®Google Scholar